CD274 and breast cancer: In contrast to other tumors (melanoma, lung cancer, and colorectal cancer), in which several data support TMB as a predictive biomarker for ICI efficacy, regardless of PD-L1 expression, its clinical utility in BC is not well known due to the limited and controversial data available.